Aquestive Therapeutics (NASDAQ:AQST) Stock Price Down 4.6% – Time to Sell?

Aquestive Therapeutics, Inc. (NASDAQ:AQST) shares were down 4.6% on Tuesday . The company traded as low as $6.27 and last traded at $6.3180. Approximately 485,085 shares traded hands during trading, a decline of 76% from the average daily volume of 2,024,996 shares. The stock had previously closed at $6.62.

Analyst Upgrades and Downgrades

AQST has been the subject of a number of research reports. Citigroup reissued an “outperform” rating on shares of Aquestive Therapeutics in a research note on Thursday, October 9th. Wall Street Zen raised Aquestive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, November 8th. Zacks Research upgraded Aquestive Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Friday, October 17th. Oppenheimer upped their price target on Aquestive Therapeutics from $7.00 to $8.00 and gave the stock an “outperform” rating in a research note on Monday, September 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Aquestive Therapeutics in a research report on Wednesday, October 8th. Two research analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average price target of $10.00.

Aquestive Therapeutics Stock Performance

The stock has a 50 day simple moving average of $6.30 and a 200-day simple moving average of $4.82.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.01). The firm had revenue of $12.81 million during the quarter, compared to analysts’ expectations of $12.94 million. As a group, equities research analysts forecast that Aquestive Therapeutics, Inc. will post -0.46 EPS for the current fiscal year.

Insider Activity

In related news, insider Peter E. Boyd sold 10,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $7.00, for a total value of $70,000.00. Following the completion of the transaction, the insider directly owned 268,323 shares in the company, valued at $1,878,261. The trade was a 3.59% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Cassie Jung sold 67,575 shares of the company’s stock in a transaction that occurred on Wednesday, October 15th. The shares were sold at an average price of $7.01, for a total value of $473,700.75. Following the completion of the transaction, the chief operating officer directly owned 240,771 shares in the company, valued at $1,687,804.71. This trade represents a 21.92% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 199,590 shares of company stock valued at $1,301,803 over the last ninety days. 8.35% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the business. NewEdge Advisors LLC bought a new stake in Aquestive Therapeutics in the 3rd quarter worth approximately $28,000. BNP Paribas Financial Markets grew its holdings in shares of Aquestive Therapeutics by 78.3% in the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock worth $31,000 after acquiring an additional 4,134 shares during the period. USAdvisors Wealth Management LLC bought a new stake in shares of Aquestive Therapeutics in the second quarter worth $33,000. Modern Wealth Management LLC purchased a new stake in Aquestive Therapeutics during the second quarter valued at $33,000. Finally, First National Bank & Trust Co. of Newtown bought a new position in Aquestive Therapeutics in the second quarter valued at about $50,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.